Warfarin intolerance, inability to adhere to warfarin monitoring requirements, inadequate INR control with warfarin (two INR values greater than 5 or less than 1.5 in the past six months) are other indications. Dabigatran, rivaroxaban and epixaban are FDA-approved for primary prevention of VTE after total hip (35 days) and knee (14 days) replacement too. In addition, rivaroxaban has obtained FDA approval for acute treatment of acute coronary syndrome. Established indications approved by the United States Food and Drug Administration (FDA) include stroke prophylaxis and systemic embolisation in non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) treatment and secondary prophylaxis.
Direct acting oral anticoagulants (DOAC) include dabigatran (Pradaxa direct thrombin (Factor IIa) inhibitor) and rivaroxaban (Xarelto), apixaban (Eliquis), endoxaban (Savaysa) and betrixaban (Bevyxxa) (direct factor Xa inhibitors).
0 kommentar(er)
